Evaluation of two mitochondrial DNA biomarkers for prostate cancer detection

Published: August 17, 2015

Author(s)

Samantha D. Maragh, Steven P. Lund

Abstract

BACKGROUND: A 3.4kb deletion (3.4kbΔ) in mitochondrial DNA (mtDNA) found in histologically normal prostate biopsy specimens has been reported to be a biomarker for the increased probability of prostate cancer. Increased mtDNA copy number is also reported as associated with cancer. OBJECTIVE: Independent evaluation of these two potential prostate cancer biomarkers using formalin-fixed paraffin-embedded (FFPE) prostate tissue and matched urine and serum from a high risk cohort of men with and without prostate cancer. METHODS: Biomarker levels were detected via qPCR. RESULTS: Both 3.4kbΔ and mtDNA levels were significantly higher in cancer patient FFPE cores (p=0.045 and p=0.070 respectively at >90% confidence). Urine from cancer patients contained significantly higher levels of mtDNA (p=0.006, 64.3% sensitivity, 86.7% specificity). Combining the 3.4kbΔ and mtDNA gave better performance of detecting prostate cancer than either biomarker alone (FFPE 73.7% sensitivity, 65% specificity; urine 64.3% sensitivity, 100% specificity). In serum, there was no difference for any of the biomarkers. CONCLUSIONS: This is the first report on detecting the 3.4kbΔ in urine and evaluating mtDNA levels as a prostate cancer biomarker. A confirmation study with increased sample size and possibly with additional biomarkers would need to be conducted to corroborate and extend these observations.
Citation: Cancer Biomarkers
Volume: 15
Issue: 6
Pub Type: Journals

Keywords

prostate, cancer, biomarker, mitochondrial DNA, 3.4kb deletion, urine, serum, FFPE, NIST, EDRN
Created August 17, 2015, Updated November 10, 2018